Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipifarnib in Myelodysplastic Syndromes
NCT02779777Phase 2Terminated
- Sponsor
- Kura Oncology
- Start
- Jun 2016
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tipifarnib in myelodysplastic syndrome (MDS) (2 arms), sponsored by Kura Oncology. Primary endpoint: Objective Response Rate at 1 year. Started Jun 2016; status: terminated.
02
Drugs
tipifarnib
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02779777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02779777.